MLTX
MoonLake Immunotherapeutics
$10.10
+$0.29(+2.96%)
29
Overall
40
Value
9
Tech
39
Quality
Market Cap
$3.42B
Volume
2.18M
52W Range
$5.95 - $62.75
Target Price
$17.08
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $2.3M | -- | -- | -- | ||
| Total Revenue | $2.3M | -- | -- | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $2.3M | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $4.6M | $65.1M | $54.1M | $143.1M | ||
| Research & Development | -- | $42.0M | $31.8M | $112.8M | ||
| Research Expense | -- | $42.0M | $31.8M | $112.8M | ||
| Selling, General & Administrative | $4.6M | $23.0M | $22.3M | $30.3M | ||
| General & Administrative Expenses | $4.6M | $23.0M | $22.3M | $30.3M | ||
| Salaries & Wages | -- | $-9.7M | $-7.1M | $-7.3M | ||
| Depreciation & Amortization | -- | -- | $400.0K | $1.4M | ||
| Depreciation & Amortization | -- | -- | $400.0K | $1.4M | ||
| Other Operating Expenses | $-4.0M | $-374.3K | $488.0K | $1.4M | ||
| OPERATING INCOME | ||||||
| Operating income | $-4.6M | $-65.1M | $-54.1M | $-143.1M | ||
| EBITDA | $-4.6M | $-64.5M | $-43.6M | $-119.6M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $27.7K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $27.7K | -- | -- | -- | ||
| Other Income/Expense | $-9.1M | $591.7K | $-10.1M | $-22.1M | ||
| Other Special Charges | -- | $591.7K | $10.1M | $22.1M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-4.6M | $-64.5M | $-44.0M | $-121.0M | ||
| Pre-Tax Income | $-4.5M | $-64.5M | $-44.0M | $-121.0M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | $36.4K | $94.4K | $282.2K | ||
| NET INCOME | ||||||
| Net Income | $-4.5M | $-50.0M | $-36.0M | $-118.9M | ||
| Net Income (Continuing Operations) | $-4.5M | $-64.5M | $-44.1M | $-121.2M | ||
| Net Income (Discontinued Operations) | $-4.5M | $-50.0M | $-36.0M | $-118.9M | ||
| Net Income (Common Stockholders) | $-4.5M | $-50.0M | $-36.0M | $-118.9M | ||
| Normalized Income | -- | -- | -- | $-119.8M | ||
| TOTALS | ||||||
| Total Expenses | $4.6M | $65.1M | $54.1M | $143.1M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $11.9M | $29.4M | $49.1M | $62.9M | ||
| Average Shares Outstanding (Diluted) | $360.0M | $29.4M | $49.1M | $62.9M | ||
| Shares Outstanding | $14.8M | $52.7M | $63.9M | $64.0M | ||
| Basic EPS | -- | $-1.7 | $-0.73 | $-1.89 | ||
| Basic EPS (Continuing Operations) | -- | $-1.7 | $-0.73 | $-1.89 | ||
| Diluted EPS | $-0.31 | $-1.7 | $-0.73 | $-1.89 | ||
| Diluted EPS (Continuing Operations) | -- | $-1.7 | $-0.73 | $-1.89 | ||
| OTHER METRICS | ||||||
| Fees | $2.3M | -- | -- | -- | ||
| Minority Interests | -- | $14.5M | $8.1M | $2.3M | ||
| Other Gand A | $4.6M | $23.0M | $22.3M | $30.3M | ||
| Rent And Landing Fees | $4.6M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MLTX | $10.10 | +3.0% | 2.18M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get MoonLake Immunotherapeutics Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW